TIGIT is often co-expressed with PD-1 and other immune checkpoints on CD8+TILs.Dual PD-1/TIGIT blockers have achieved higher clinical efficacy in melanoma compared with single immune checkpoint inhibition confirming the potential possibility of TIGIT as an immunotherapy target (16, 17). The gene discussed is TIGIT; the disease is melanoma.